AIFM2 and non-small cell lung carcinoma: These findings suggested that targeting the miR-4443/METTL3/FSP1 axis could be a potential therapeutic strategy to overcome cisplatin resistance in NSCLC by inducing ferroptosis (Song et al., 2021).